<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655210</url>
  </required_header>
  <id_info>
    <org_study_id>HL_HL151_301</org_study_id>
    <nct_id>NCT03655210</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients</brief_title>
  <official_title>4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic confirmatory Clinical
      Trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic confirmatory Clinical
      Trial to Evaluate the Efficacy and Safety of HL151 versus Placebo in perennial allergic
      rhinitis patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Actual">October 16, 2017</completion_date>
  <primary_completion_date type="Actual">February 20, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in total rTNSS(Reflective TNSS) score</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (2 weeks), Visit 4 (4 weeks)</time_frame>
    <description>Changes in total rTNSS(Reflective TNSS) score at 4 weeks after clinical drug administration compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in rTNSS(Reflective TNSS) score</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (2 weeks)</time_frame>
    <description>Changes in rTNSS(Reflective TNSS) score at 2 weeks after clinical drug administration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in iTNSS(Instananeous TNSS) score</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (2 weeks), Visit 4 (4 weeks)</time_frame>
    <description>Changes in iTNSS(Instananeous TNSS) score at 2 weeks and 4 weeks after clinical drug administration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rTNSS(Reflective TNSS) score (Information recorded in the TNSS section of the diary included-Runny Nose,Sneezing,Itchy)</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (2 weeks), Visit 4 (4 weeks)</time_frame>
    <description>Changes in rTNSS(Reflective TNSS) score (Information recorded in the TNSS section of the diary included-Runny Nose,Sneezing,Itchy) at 2 weeks and 4 weeks after clinical drug administration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in iTNSS(Instananeous TNSS) score (Information recorded in the TNSS section of the diary included-Runny Nose,Sneezing,Itchy)</measure>
    <time_frame>Visit 2 (0 week), Visit 3 (2 weeks), Visit 4 (4 weeks)</time_frame>
    <description>Changes in iTNSS(Instananeous TNSS) score (Information recorded in the TNSS section of the diary included-Runny Nose,Sneezing,Itchy) at 2 weeks and 4 weeks after clinical drug administration compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's assessment of overall treatment</measure>
    <time_frame>Visit 4 (4 weeks)</time_frame>
    <description>Investigator's assessment of overall treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL151</intervention_name>
    <description>HL151(1Tab) once a day for 4 weeks of treatments</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both gender, 19 years â‰¤ age

          2. At least two years history of allergic rhinitis prior to participate in clinical trial

          3. Patients with positive reaction for perennial allergen in tests(prick test or
             Intradermal test or MAST(Multiple Allergen Simultaneous Test) or Immuno CAP test)
             within 12 months

          4. In visit 2, patients with over mean 5 points of the total reflective TNSS score per
             day (during the run-in period) (highest value 12 points)

          5. Patients who can ability to record subject diary

          6. Patients who agreed to maintain the same environment throughout the entire clinical
             trial period.

          7. Written consent voluntarily to participate in this clinical trial after understanding
             and detailed explanation about this clinical trial

        Exclusion Criteria:

          1. Patients with non-allergic rhinitis

          2. Patients with asthma due to the following diseases(but patients with mild and
             intermittent asthma are available to participate in clinical trials)

               -  Within four weeks from the date of screening, patients who visit the emergency
                  room or have been hospitalized within 12 weeks or

               -  patients with asthma who need other treatment except short-acting Beta-efficient
                  respiratory relaxants Inhalation

          3. Patients with obstructive nasal polyp or severe deviated nasal septum

          4. Patients who Within 12 weeks from the date of screening, had damage or surgery around
             nasal cavity

          5. Patients with anamnesis in acute /chronic sinusitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

